Equities research analysts at Cantor Fitzgerald increased their FY2024 earnings estimates for PTC Therapeutics in a report ...

William Blair increased their FY2024 earnings estimates for PTC Therapeutics in a report issued on Monday, January 13th.

Cantor Fitzgerald lowered the firm’s price target on PTC Therapeutics (PTCT) to $76 from $80 and keeps an Overweight rating on the shares. The ...

Check the time stamp on this data. Updated AI-Generated Signals for Ptc Therapeutics Inc. (PTCT) available here: PTCT. Type a ...

PTC Therapeutics (PTCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Lebowitz ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing the right to receive one share of its common ...

WARREN, N.J., Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at ...

WARREN, N.J., Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing ...